ALB and liver dysplastic nodule: A great amount of randomized controlled trials (RCTs) have suggested that CHM alone or combined with ACEI/ARB has therapeutic potential in the treatment of DN can improve reducing urinary albumin excretion, ameliorating proteinuria, and symptoms.[16] However, there is still lack of relative systematic evidence-based medical evidence about CHM in treating patients with early DN currently.